-+undefined NaN%
-+undefined NaN%
-+undefined NaN%

Madrigal Announces Additional Results From Pivotal Phase 3 MAESTRO-NASH Clinical Trial Of Resmetirom For Treatment Of NASH With Liver Fibrosis

Benzinga · 01/06/2023 08:01
  • As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH trial
     
  • A supportive analysis using consensus reads of digitized biopsy images by the central pathologists replicated the positive primary endpoint results
  • These data will be presented at the NASH-TAG Conference on Friday January 6th, 2023